<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01936974</url>
  </required_header>
  <id_info>
    <org_study_id>13-27</org_study_id>
    <nct_id>NCT01936974</nct_id>
  </id_info>
  <brief_title>(PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma</brief_title>
  <acronym>PGA</acronym>
  <official_title>Platinum-Gemcitabine-Avastin (PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Western Regional Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Western Regional Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate progression-free survival with two chemotherapy regimens on
      platinum-resistant/refractory ovarian and peritoneal carcinoma
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will evaluate progression-free survival (PFS)for the regimen of gemcitabine and
      bevacizumab with or without a platinum agent on platinum-resistant/refractory ovarian and
      peritoneal carcinoma
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    PI Decision
  </why_stopped>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>One Year</time_frame>
    <description>Evaluate progression-free survival between the two regimens.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Ovarian Carcinoma</condition>
  <condition>Fallopian Tube Carcinoma</condition>
  <condition>Peritoneal Carcinoma</condition>
  <arm_group>
    <arm_group_label>Platinum, Gemcitabine and Bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Platinum:
Carboplatin* on day 1
*If a patient is allergic to carboplatin, then give
Cisplatin** on day 1
**If a patient is allergic to cisplatin and carboplatin, then give
Oxaliplatin on day 1
Gemcitabine on day 1 only
Bevacizumab on day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gemcitabine and Bevacizumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Gemcitabine on days 1 and 8
Bevacizumab on day 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Patient to receive gemzar</description>
    <arm_group_label>Platinum, Gemcitabine and Bevacizumab</arm_group_label>
    <arm_group_label>Gemcitabine and Bevacizumab</arm_group_label>
    <other_name>Gemzar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Patient to receive avastin</description>
    <arm_group_label>Platinum, Gemcitabine and Bevacizumab</arm_group_label>
    <arm_group_label>Gemcitabine and Bevacizumab</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Patient to receive carboplatin</description>
    <arm_group_label>Platinum, Gemcitabine and Bevacizumab</arm_group_label>
    <other_name>Paraplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Patient to receive cisplatin</description>
    <arm_group_label>Platinum, Gemcitabine and Bevacizumab</arm_group_label>
    <other_name>Platinol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>Patient to receive Oxaliplatin</description>
    <arm_group_label>Platinum, Gemcitabine and Bevacizumab</arm_group_label>
    <other_name>Eloxatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients ≥ 18 years of age with histologically confirmed, recurrent epithelial
             ovarian, fallopian tube, or primary peritoneal cancer

          2. Disease progression during or within 6 months of previous platinum-based chemotherapy
             including the following 4 categories:

               1. Primary platinum-refractory: Previously untreated patients who do not achieve at
                  least a partial response to platinum-based chemotherapy

               2. Primary platinum-resistant: Previously untreated patients who have achieved at
                  least a partial response to platinum-based chemotherapy but experience a relapse
                  within a period of 6 months of its conclusion

               3. Secondary platinum-refractory: Previously treated patients have a relapse 6
                  months after the conclusion of chemotherapy, but fail to achieve at least a
                  partial response

               4. Secondary platinum-resistant: Previously treated patients have a relapse 6 months
                  after the conclusion of chemotherapy, achieve at least a partial response with
                  platinum-based therapy as 2nd-line therapy, but experience relapse within 6
                  months

          3. Eastern Cooperative Oncology Group (ECOG) performance status score ≤ 2 and a life
             expectancy &gt;3 months.

          4. Absolute neutrophil count &gt; 1500 mm^3, platelet count ≥ 100×10^9 L, hemoglobin ≥ 8.5
             g/dL

          5. Serum creatinine ≤1.5 times the upper limit of the normal range, total bilirubin ≤ 2
             mg/dL, AST/ALT ≤ 5 times the upper limit of normal range

          6. No remaining grade 2 or higher toxicity from prior cancer therapies unless judged to
             be clinically insignificant by the Principal Investigator

          7. At least three (3) weeks from prior chemotherapy

        Exclusion Criteria:

          1. Inadequate renal function with a calculated creatinine clearance less than 51 mL/min

          2. Uncontrolled cardiac disease, congestive heart failure, angina, or hypertension

          3. Myocardial infarction or unstable angina within 2 months of treatment

          4. Known human immunodeficiency virus (HIV) infection or chronic active Hepatitis B or C
             (patients are NOT required to be tested for the presence of such viruses prior to
             therapy on this protocol)

          5. Thrombotic or embolic events such as a cerebrovascular accident including transient
             ischemic attacks, pulmonary embolism within the past 6 months

          6. Bleeding diathesis or significant coagulopathy

          7. Pulmonary hemorrhage/bleeding event ≥ CTCAE Grade 2 within 4 weeks of first dose of
             study drug

          8. Any other hemorrhage/bleeding event ≥ CTCAE Grade 3 within 4 weeks of first dose of
             study drug

          9. History of fistula, GI perforation, or intrabdominal abscess

         10. Serious non-healing wound, ulcer, or bone fracture

         11. clinical signs or symptoms of GI obstruction and/or requirement for parenteral
             hydration or nutrition

         12. Known CNS disease except for treated brain metastasis

         13. Known platinum drug allergy

         14. Prior treatment with Platinum + Gemcitabine + Avastin, Gemcitabine + Avastin or
             Gemcitabine alone

         15. Prior treatment with more than three (3) lines of chemotherapy including adjuvant
             chemotherapy

         16. Major surgery, open biopsy or significant traumatic injury within 4 weeks of first
             study drug

         17. Inability to complete informed consent process and adhere to the protocol treatment
             plan and follow-up requirements

         18. Concurrent severe illness such as active infection, or psychiatric illness/social
             situations that would limit safety and compliance with study requirements
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jordan Waypa, FNP</last_name>
    <role>Study Director</role>
    <affiliation>Western Regional Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Western Regional Medical Center</name>
      <address>
        <city>Goodyear</city>
        <state>Arizona</state>
        <zip>85338</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 3, 2013</study_first_submitted>
  <study_first_submitted_qc>September 3, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 6, 2013</study_first_posted>
  <results_first_submitted>September 27, 2017</results_first_submitted>
  <results_first_submitted_qc>September 27, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">October 25, 2017</results_first_posted>
  <last_update_submitted>January 22, 2018</last_update_submitted>
  <last_update_submitted_qc>January 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Platinum, Gemcitabine and Bevacizumab</title>
          <description>Platinum:
Carboplatin* on day 1
*If a patient is allergic to carboplatin, then give
Cisplatin** on day 1
**If a patient is allergic to cisplatin and carboplatin, then give
Oxaliplatin on day 1
Gemcitabine on day 1 only
Bevacizumab on day 1
Gemcitabine
Bevacizumab
Carboplatin
Cisplatin
Oxaliplatin</description>
        </group>
        <group group_id="P2">
          <title>Gemcitabine and Bevacizumab</title>
          <description>Gemcitabine on days 1 and 8
Bevacizumab on day 1
Gemcitabine
Bevacizumab</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline data were not collected. No data was collected for this study.</population>
      <group_list>
        <group group_id="B1">
          <title>Platinum, Gemcitabine and Bevacizumab</title>
          <description>Platinum:
Carboplatin* on day 1
*If a patient is allergic to carboplatin, then give
Cisplatin** on day 1
**If a patient is allergic to cisplatin and carboplatin, then give
Oxaliplatin on day 1
Gemcitabine on day 1 only
Bevacizumab on day 1
Gemcitabine
Bevacizumab
Carboplatin
Cisplatin
Oxaliplatin</description>
        </group>
        <group group_id="B2">
          <title>Gemcitabine and Bevacizumab</title>
          <description>Gemcitabine on days 1 and 8
Bevacizumab on day 1
Gemcitabine
Bevacizumab</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="0"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="0"/>
          </count_list>
        </analyzed>
      </analyzed_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression-free Survival</title>
        <description>Evaluate progression-free survival between the two regimens.</description>
        <time_frame>One Year</time_frame>
        <population>Data not collected. The study has been terminated due to the PI no longer being employed at CTCA and not having rights to the trial information.After much effort, results were not able to be retained.</population>
        <group_list>
          <group group_id="O1">
            <title>Platinum, Gemcitabine and Bevacizumab</title>
            <description>Platinum:
Carboplatin* on day 1
*If a patient is allergic to carboplatin, then give
Cisplatin** on day 1
**If a patient is allergic to cisplatin and carboplatin, then give
Oxaliplatin on day 1
Gemcitabine on day 1 only
Bevacizumab on day 1
Gemcitabine
Bevacizumab
Carboplatin
Cisplatin
Oxaliplatin</description>
          </group>
          <group group_id="O2">
            <title>Gemcitabine and Bevacizumab</title>
            <description>Gemcitabine on days 1 and 8
Bevacizumab on day 1
Gemcitabine
Bevacizumab</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival</title>
          <description>Evaluate progression-free survival between the two regimens.</description>
          <population>Data not collected. The study has been terminated due to the PI no longer being employed at CTCA and not having rights to the trial information.After much effort, results were not able to be retained.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Data not collected. The study has been terminated due to the PI no longer being employed at CTCA and not having rights to the trial information.&quot;After much effort, results were not able to be retained.</time_frame>
      <desc>Data not collected. The study has been terminated due to the PI no longer being employed at CTCA and not having rights to the trial information.&quot;After much effort, results were not able to be retained.</desc>
      <group_list>
        <group group_id="E1">
          <title>Platinum, Gemcitabine and Bevacizumab</title>
          <description>Platinum:
Carboplatin* on day 1
*If a patient is allergic to carboplatin, then give
Cisplatin** on day 1
**If a patient is allergic to cisplatin and carboplatin, then give
Oxaliplatin on day 1
Gemcitabine on day 1 only
Bevacizumab on day 1
Gemcitabine
Bevacizumab
Carboplatin
Cisplatin
Oxaliplatin</description>
        </group>
        <group group_id="E2">
          <title>Gemcitabine and Bevacizumab</title>
          <description>Gemcitabine on days 1 and 8
Bevacizumab on day 1
Gemcitabine
Bevacizumab</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jessica Coats, RN</name_or_title>
      <organization>CTCA</organization>
      <phone>6232073899</phone>
      <email>jessica.coats@ctca-hope.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

